AbstractObjective To evaluate the clinical efficacy and safety of CT-guided 125I seed implantation in the treatment of recurrent head and neck tumors after radiotherapy. Methods Clinical data of 101 patients who received CT-guided radioactive 125I seed implantation for recurrent head and neck cancer after radiotherapy from 2007 to 2015 were retrospectively analyzed. The median accumulated dose of external radiotherapy was 66 Gy and the median dose after seed implantation(D90) was 117 Gy. The local progression-free survival and overall survival were analyzed by Kaplan-Meier method. Univariate analysis was performed by log-rank test and multivariate analysis was conducted by using Cox regression model. Results The median follow-up time was 12.2 months. The 5-year local progression-free survival rate was 26.6%.The 5-year overall survival rate was 15.5%. Univariate analysis demonstrated that age,pathological type,implantation site,lesion volume,D90and short-term efficacy were correlated with local control,and KPS score,lesion volume,D90,and short-term efficacy were associated with survival (all P<0.05). Multivariate analysis revealed that pathological type,lesion volume,D90 and short-term efficacy were independent factors related to local control (P=0.000,0.002,0.003 and 0.014).In terms of the adverse events,skin/mucosal ulceration was observed in 25.7% and pain occurred in 13.9% of all patients. No correlation was noted between the adverse events and dose. Conclusions CT-guided radioactive 125I seed implantation is an efficacious and safe treatment of recurrent head and neck tumors after radiotherapy. Non-squamous carcinoma,small lesion volume and high dose(D90) indicate excellent local control.
Fund:Capital Featured Clinical Application Research Project (Z151100004015171)
Corresponding Authors:
Wang Junjie,Email:junjiewang_edu@sina.cn
Cite this article:
Ji Zhe,Jiang Yuliang,Guo Fuxin et al. Clinical efficacy of CT-guided iodine-125 seed implantation for recurrent head and neck carcinoma after external beam radiotherapy[J]. Chinese Journal of Radiation Oncology, 2018, 27(9): 793-797.
Ji Zhe,Jiang Yuliang,Guo Fuxin et al. Clinical efficacy of CT-guided iodine-125 seed implantation for recurrent head and neck carcinoma after external beam radiotherapy[J]. Chinese Journal of Radiation Oncology, 2018, 27(9): 793-797.
[1] Farrag A,Voordeckers M,Tournel K,et al. Pattern of failure after helical tomotherapy in head and neck cancer[J].Strahlenther Onkol,2010,186(9):511-516.DOI:10.1007/s00066-010-2130-5. [2] Patel PR,Salama JK.Reirradiation for recurrent head and neck cancer[J].Expert Rev Anticancer Ther,2012,12(9):1177-1189.DOI:10.1586/era.12.97. [3] Temam S,Pape E,Janot F,et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma[J].Int J Radiat Oncol Biol Phys,2005,62(4):1078-83.DOI:10.1016/j.ijrobp.2004.12.062. [4] Wong SJ,Machtay M,Li Y.Locally recurrent,previously irradiated head and neck cancer:concurrent re-irradiation and chemotherapy,or chemotherapy alone?[J].J Clin Oncol,2006,24(17):2653-2658.DOI:10.1200/jco.2005.05.3850. [5] Clavel M,Vermorken JB,Cognetti F,et al. Randomized comparison of cisplatin,methotrexate,bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase Ⅲ study of the EORTC Head and Neck Cancer Cooperative Group[J].Ann Oncol,1994,5(6):521-526. [6] Schornagel JH,Verweij J,de Mulder PH,et al. Randomized phase Ⅲ trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck:a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study[J].J Clin Oncol,1995,13(7):1649-1655.DOI:10.1200/jco.1995.13.7.1649. [7] De Crevoisier R,Bourhis J,Domenge C,et al. Full-dose reirradiation for unresectable head and neck carcinoma:experience at the Gustave-Roussy Institute in a series of 169 patients[J].J Clin Oncol,1998,16(11):3556-3562.DOI:10.1200/jco.1998.16.11.3556. [8] Lee N,ChanK,Bekelman JE,et al. Salvage re-irradiation for recurrent head and neck cancer[J].Int J Radiat Oncol Biol Phys,2007,68(3):731-740.DOI:10.1016/j.ijrobp.2006.12.055. [9] Wierzbicka M,Bartochowska A,Strnad V,et al. The role of brachytherapy in the treatment of squamous cell carcinoma of the head and neck[J].Eur Arch Otorhinolaryngol,2016.273(2):269-276.DOI:10.1007/s00405-014-3332-8. [10] Lin L,Wang J,Jiang Y,et al. Interstitial 125I seed implantation for cervical lymph node recurrence after multimodal treatment of thoracic esophageal squamous cell carcinoma[J].Technol Cancer Res Treat,2015,14(2):201-207.DOI:10.7785/tcrt.2012.500409. [11] Eisenhauer EA,Therasse P,Bogaerts J,et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.DOI:10.1016/j.ejca.2008.10.026. [12] Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.2010[2018-01-20]. Available from:https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. [13] Mobit P,Badragan I.An evaluation of the AAPM-TG43 dosimetry protocol for I-125 brachytherapy seed[J].Phys Med Biol,2004,49(14):3161-3170. [14] Jiang P,Jiang Y,Wang JJ,et al. Percutaneous ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent head and neck carcimonas[J].Cancer Biother Radiopharm,2011,26(6):753-757.DOI:10.1089/cbr.2010.0844. [15] Zhu L,Jiang Y,Wang J,et al. An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy[J].World J Surg Oncol,2013,11:60.DOI:10.1186/1477-7819-11-60. [16] Sulman EP,Schwartz DL,Le TT,et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes[J].Int J Radiat Oncol Biol Phys,2009,73(2):399-409.DOI:10.1016/j.ijrobp.2008.04.021. [17] Voynov G,Heron DE,Burton S,et al. Frameless stereotactic radiosurgery for recurrent head and neck carcinoma[J].Technol Cancer Res Treat,2006,5(5):529-35.DOI:10.1177/153303460600500510. [18] Ozyigit G,Cengiz M,Yazici G,et al. A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma[J].Int J Radiat Oncol Biol Phys,2011,81(4):e263-8.DOI:10.1016/j.ijrobp.2011.02.054. [19] Langer CJ,Harris J,Horwitz EM,et al. Phase Ⅱ study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck:results of Radiation Therapy Oncology Group Protocol 9911[J].J Clin Oncol,2007,25(30):4800-4805.DOI:10.1200/jco.2006.07.9194. [20] Roh KW,Jang JS,Kim MS,et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer[J].Int J Radiat Oncol Biol Phys,2009,74(5):1348-1355.DOI:10.1016/j.ijrobp.2008.10.013. [21] Meng N,Jiang YL,Wang JJ,et al. Permanent implantation of iodine-125 seeds as a salvage therapy for recurrent head and neck carcinoma after radiotherapy[J].Cancer Invest,2012,30(3):236-242.DOI:10.3109/07357907.2012.654869. [22] Zaorsky NG,Davis BJ,Nguyen PL,et al. The evolution of brachytherapy for prostate cancer[J].Nat Rev Urol,2017,14(7):415-439.DOI:10.1038/nrurol.2017.76.
2018, Vol. 27 
